| Paclitaxel studied in …STUDIED_INderived200 of 2,325show all (up to 200) |
|---|
| → studied in | NCT03734029Phase 3 · completed Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 2,325 trials list this drug (526 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · 2,325 trials list this drug (526 active) | — | — | Endometrial Carcinoma,Endometrial Endometrioid Adenocarcinoma,Endometrial Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 2,325 trials list this drug (526 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Neoplasm,Solid Neoplasm,Adult Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06619236Phase 3 · active not recruiting Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694454Phase 1/Phase 2 · suspended Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788912Phase 2 · active not recruiting Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07060807Phase 3 · recruiting A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · 2,325 trials list this drug (526 active) | — | — | Cervical Adenocarcinoma,Cervical Squamous Cell Carcinoma,Cervical Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253964Phase 2 · recruiting Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Non-Small Cell Squamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04472429Phase 3 · completed Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06103864Phase 3 · recruiting A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · 2,325 trials list this drug (526 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312137Phase 3 · recruiting A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312176Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385080Phase 1/Phase 2 · recruiting A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer · 2,325 trials list this drug (526 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · 2,325 trials list this drug (526 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966700Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07007559Phase 2 · recruiting ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07195734Phase 2 · recruiting Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Malignant Laryngeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07198074Phase 3 · recruiting Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer · 2,325 trials list this drug (526 active) | — | — | Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07216703Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) · 2,325 trials list this drug (526 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07219212Phase 1 · recruiting A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2,325 trials list this drug (526 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07419295Phase 3 · recruiting A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · 2,325 trials list this drug (526 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00295893Phase 2 · active not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02390427Phase 1 · completed Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03716180Phase 1 · active not recruiting DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06018337Phase 3 · active not recruiting A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · 2,325 trials list this drug (526 active) | — | — | Melanoma,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06096844Phase 3 · recruiting Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07465757Phase 2 · recruiting A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) · 2,325 trials list this drug (526 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04400695Phase 3 · recruiting A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715229Phase 2 · terminated Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07063745Phase 2/Phase 3 · recruiting A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion · 2,325 trials list this drug (526 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07136142Phase 1/Phase 2 · recruiting A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965689Phase 2 · active not recruiting Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Non-Small Cell Squamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058377Phase 3 · recruiting Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · 2,325 trials list this drug (526 active) | — | — | HER2-Negative Breast Carcinoma,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06524544Phase 3 · recruiting A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer · 2,325 trials list this drug (526 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06712316Phase 2/Phase 3 · recruiting Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07213804Phase 3 · recruiting A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Peritoneal Neoplasm,Fallopian Tube Neoplasm,Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07265739Phase 2 · not yet recruiting Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528768Phase 2 · not yet recruiting HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. · 2,325 trials list this drug (526 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644068Phase 1/Phase 2 · active not recruiting Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,Malignant Gastric Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06745882Phase 2 · recruiting Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04090398Phase 2 · active not recruiting Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones · 2,325 trials list this drug (526 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04634877Phase 3 · active not recruiting Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) · 2,325 trials list this drug (526 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04752826Phase 1/Phase 2 · recruiting BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) · 2,325 trials list this drug (526 active) | — | — | Melanoma,Ovarian Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692738Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06340568Phase 3 · recruiting A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06952504Phase 3 · recruiting A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) · 2,325 trials list this drug (526 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824869Phase 2 · not yet recruiting A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579224Phase 3 · active not recruiting Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer · 2,325 trials list this drug (526 active) | — | — | Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05751668Phase 2 · active not recruiting Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05798819Phase 3 · recruiting A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07492680Phase 2 · recruiting A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) · 2,325 trials list this drug (526 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07680764Phase 2 · recruiting A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05739981Phase 1/Phase 2 · recruiting Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06915025Phase 3 · recruiting Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer · 2,325 trials list this drug (526 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04266249Phase 2 · active not recruiting CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy · 2,325 trials list this drug (526 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721755Phase 3 · active not recruiting Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck · 2,325 trials list this drug (526 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06449209Phase 2 · active not recruiting Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy · 2,325 trials list this drug (526 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04444921Phase 3 · active not recruiting EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients · 2,325 trials list this drug (526 active) | — | — | Anal Squamous Cell Carcinoma,Anal Basaloid Carcinoma,Anal Canal Cloacogenic Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226598Phase 3 · terminated Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05365581Phase 1 · recruiting A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer · 2,325 trials list this drug (526 active) | — | — | Gastric Adenocarcinoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06535607Phase 2 · recruiting Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06840002Phase 1/Phase 2 · recruiting A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06843447Phase 1/Phase 2 · recruiting A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06964009Phase 1 · recruiting DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Ovarian Neoplasm,Malignant Ovarian Neoplasm,Ovarian Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743164Phase 3 · not yet recruiting A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) · 2,325 trials list this drug (526 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01142388Phase 2 · active not recruiting Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Esophageal Neoplasm,Esophageal Carcinoma,Esophageal Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02135042Phase 2/Phase 3 · active not recruiting Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA · 2,325 trials list this drug (526 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02259621Phase 2 · active not recruiting Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04310007Phase 2 · active not recruiting Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06797635Phase 2 · recruiting Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07811375Phase 2 · not yet recruiting Perioperative Adebrelimab for Locally Advanced Cervical Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00977574Phase 2 · active not recruiting Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer · 2,325 trials list this drug (526 active) | — | — | Endometrial Adenocarcinoma,Endometrial Serous Adenocarcinoma,Endometrial Adenosquamous Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907475Phase 2 · recruiting Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04001829Phase 2 · active not recruiting Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07604766Phase 3 · recruiting An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China · 2,325 trials list this drug (526 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092283Phase 3 · active not recruiting Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04339738Phase 2 · active not recruiting Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma · 2,325 trials list this drug (526 active) | — | — | Skin Angiosarcoma,Skin Radiation-Related Angiosarcoma,Visceral Angiosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05307705Phase 1 · recruiting A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561685Phase 1 · recruiting A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01366144Phase 1 · active not recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction · 2,325 trials list this drug (526 active) | — | — | Malignant Neoplasm,Malignant Head and Neck Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04391049Phase 1 · active not recruiting Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery · 2,325 trials list this drug (526 active) | — | — | Squamous Cell Carcinoma,Esophageal Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07281417Phase 2 · recruiting Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma · 2,325 trials list this drug (526 active) | — | — | Malignant Sinonasal Neoplasm,Sinonasal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07300475Phase 1 · not yet recruiting Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients · 2,325 trials list this drug (526 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07640932Phase 2 · not yet recruiting Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04069273Phase 2 · active not recruiting Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma · 2,325 trials list this drug (526 active) | — | — | Gastric Neoplasm,Adenocarcinoma,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892953Phase 2 · recruiting Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06245889Phase 2 · recruiting PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC · 2,325 trials list this drug (526 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06422143Phase 3 · recruiting Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06445972Phase 1/Phase 2 · recruiting Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · 2,325 trials list this drug (526 active) | — | — | Esophageal Neoplasm,Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06727565Phase 2 · active not recruiting Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 · 2,325 trials list this drug (526 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06989112Phase 3 · recruiting DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07684612Phase 3 · not yet recruiting A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) · 2,325 trials list this drug (526 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319730Phase 1/Phase 2 · recruiting A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) · 2,325 trials list this drug (526 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05506943Phase 2/Phase 3 · active not recruiting A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) · 2,325 trials list this drug (526 active) | — | — | Malignant Biliary Tract Neoplasm,Cholangiocarcinoma,Ampulla of Vater Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04209686Phase 2 · completed Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma · 2,325 trials list this drug (526 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05054439Phase 2 · active not recruiting A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC · 2,325 trials list this drug (526 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564141Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm,Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02305654Phase 3 · active not recruiting International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) · 2,325 trials list this drug (526 active) | — | — | Penile Squamous Cell Carcinoma, Usual Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04736173Phase 2 · active not recruiting Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06448754Phase 2 · active not recruiting Volrustomig Priming Regimens Exploratory Phase II Platform Study · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07286331Phase 3 · recruiting A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) · 2,325 trials list this drug (526 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07793942Phase 2 · not yet recruiting A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) · 2,325 trials list this drug (526 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07796126Phase 2 · not yet recruiting Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status · 2,325 trials list this drug (526 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00070564Phase 3 · active not recruiting S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00433511Phase 3 · active not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00781612Phase 2 · active not recruiting A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01081262Phase 3 · active not recruiting Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · 2,325 trials list this drug (526 active) | — | — | Borderline Ovarian Mucinous Tumor,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05298423Phase 3 · completed Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06132958Phase 3 · active not recruiting Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) · 2,325 trials list this drug (526 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04540211Phase 3 · completed A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma · 2,325 trials list this drug (526 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06492070Phase 2 · recruiting Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06783647Phase 2 · recruiting A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] · 2,325 trials list this drug (526 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03644186Phase 2 · completed To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04025879Phase 3 · active not recruiting A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05722015Phase 3 · active not recruiting A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06212752Phase 3 · active not recruiting A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07739199Phase 2/Phase 3 · not yet recruiting A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07786428Phase 2 · not yet recruiting Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC · 2,325 trials list this drug (526 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04165070Phase 1/Phase 2 · recruiting KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07102381Phase 2 · recruiting A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03801876Phase 3 · active not recruiting Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer · 2,325 trials list this drug (526 active) | — | — | Thoracic Esophagus Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554380Phase 2 · active not recruiting Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04949256Phase 3 · terminated Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). · 2,325 trials list this drug (526 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441890Phase 2 · recruiting BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221474Phase 2 · recruiting A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205968Phase 2 · recruiting Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers · 2,325 trials list this drug (526 active) | — | — | Small Intestinal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05636111Phase 1 · recruiting Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06741644Phase 1/Phase 2 · recruiting A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07775040Phase 2 · not yet recruiting Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776340Phase 2 · not yet recruiting Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740165Phase 3 · completed Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) · 2,325 trials list this drug (526 active) | — | — | Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04893109Phase 2 · recruiting ATEMPT 2.0: Adjuvant T-DM1 vs TH · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06731907Phase 2 · recruiting A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06743126Phase 3 · recruiting SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma · 2,325 trials list this drug (526 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965468Phase 2 · active not recruiting Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415709early Phase 1 · active not recruiting Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer · 2,325 trials list this drug (526 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05624996Phase 3 · recruiting Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341867Phase 1 · recruiting Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype · 2,325 trials list this drug (526 active) | — | — | Multiple Myeloma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07441681Phase 3 · recruiting Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin · 2,325 trials list this drug (526 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768436Phase 2 · recruiting A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,Breast Adenocarcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06072781Phase 3 · recruiting A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03858322Phase 1 · active not recruiting 'ADVANCE' (A Pilot Trial) · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07042802Phase 1/Phase 2 · recruiting A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00770809Phase 3 · completed Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,Male Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06139211Phase 1/Phase 2 · completed A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06543576Phase 1/Phase 2 · recruiting External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer · 2,325 trials list this drug (526 active) | — | — | Cervical Adenocarcinoma,Cervical Squamous Cell Carcinoma,Cervical Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05113251Phase 3 · active not recruiting Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06656598Phase 2 · recruiting Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07420439Phase 2 · not yet recruiting Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07602907Phase 2 · recruiting Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07756645Phase 3 · not yet recruiting A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07757022not yet recruiting AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161441Phase 2 · active not recruiting A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06926868Phase 2/Phase 3 · recruiting A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) · 2,325 trials list this drug (526 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07754812Phase 4 · recruiting Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03416153Phase 2 · completed Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Oropharyngeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04269200Phase 3 · active not recruiting Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer · 2,325 trials list this drug (526 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01547741Phase 3 · completed Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01873326Phase 2 · active not recruiting Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors · 2,325 trials list this drug (526 active) | — | — | Germ Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439693Phase 2 · recruiting The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01081951Phase 2 · active not recruiting Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01386385Phase 1/Phase 2 · active not recruiting Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery · 2,325 trials list this drug (526 active) | — | — | Lung Adenocarcinoma, Mixed Subtype,Lung Large Cell Carcinoma,Lung Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101788Phase 2/Phase 3 · completed Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · 2,325 trials list this drug (526 active) | — | — | Borderline Ovarian Serous Tumor,Micropapillary Serous Carcinoma,Ovarian Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742102Phase 1/Phase 2 · active not recruiting A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04083599Phase 1/Phase 2 · active not recruiting GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm,Melanoma,Head and Neck Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · 2,325 trials list this drug (526 active) | — | — | Low Grade Fallopian Tube Serous Adenocarcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Ovarian Seromucinous Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554341Phase 2 · active not recruiting Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06476184Phase 3 · recruiting Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06644781Phase 3 · recruiting A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) · 2,325 trials list this drug (526 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06969027Phase 2 · active not recruiting JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07744698Phase 4 · recruiting Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) · 2,325 trials list this drug (526 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03281369Phase 1/Phase 2 · terminated A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) · 2,325 trials list this drug (526 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04556773Phase 1 · active not recruiting A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · 2,325 trials list this drug (526 active) | — | — | Ovarian Endometrioid Tumor,Ovarian Serous Tumor,Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02883062Phase 2 · active not recruiting Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02905591Phase 2 · active not recruiting A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03287271Phase 1/Phase 2 · terminated ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK · 2,325 trials list this drug (526 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · 2,325 trials list this drug (526 active) | — | — | Endometrial Adenocarcinoma,Endometrial Carcinoma,Endometrial Endometrioid Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · 2,325 trials list this drug (526 active) | — | — | Hepatocellular Carcinoma,Intrahepatic Cholangiocarcinoma,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05019716Phase 1/Phase 2 · recruiting Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma · 2,325 trials list this drug (526 active) | — | — | NUT Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05673200Phase 1 · suspended Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer · 2,325 trials list this drug (526 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07121595Phase 2 · recruiting Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial · 2,325 trials list this drug (526 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Oral Cavity Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02654119Phase 2 · completed Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05747794Phase 2/Phase 3 · terminated Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy · 2,325 trials list this drug (526 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04198766Phase 1/Phase 2 · recruiting Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) · 2,325 trials list this drug (526 active) | — | — | Solid Neoplasm,Malignant Head and Neck Neoplasm,Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04245085Phase 2 · completed ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974944Phase 2 · terminated First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer · 2,325 trials list this drug (526 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05247684Phase 2 · active not recruiting AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06486441Phase 3 · active not recruiting Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) · 2,325 trials list this drug (526 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |